 |
市場調查報告書
商品編碼
2102314
Durvalumab市場規模、佔有率和成長分析：按適應症、療法、分銷管道、最終用戶、產品類型、給藥途徑和地區分類－2026-2033年產業預測Durvalumab Market Size, Share, and Growth Analysis, By Indication, By Therapy Type, By Distribution Channel, By End User, By Product Type, By Route of Administration, By Region - Industry Forecast 2026-2033 |
||||||
2024 年全球度Durvalumab市場價值為 15 億美元，預計到 2033 年將從 2025 年的 16.4 億美元成長至 32.9 億美元，預測期（2026-2033 年）的複合年成長率為 9.1%。
針對PD-L1的人源化IgG1單株抗體Durvalumab對免疫腫瘤市場產生了重大影響。此藥最初獲準用於治療不可切除的III期非小細胞肺癌（NSCLC），隨後適應症擴展至小細胞肺癌及尿路上皮癌。與標準療法相比，Durvalumab顯著提高了患者的存活率，從而促使醫生更多地採用該藥物。Astra Zeneca與基因泰克的合作擴大了Durvalumab在不同地區的市場准入，並建構了一個涵蓋製藥公司、保險公司和癌症治療中心的強大生態系統。關鍵的成長要素包括不斷擴大的適應症組合（利用查核點抑制劑機制）以及針對多種癌症的正在進行的臨床試驗。此外，人工智慧驅動的生物標記發現正在推動個人化治療方案的製定，最佳化患者選擇，並加速臨床應用。這些因素鞏固了Durvalumab的市場地位，並推動了投資成長。
全球度Durvalumab市場成長要素
全球度Durvalumab市場的主要促進因素是各種癌症，特別是非小細胞肺癌（NSCLC）和其他固體癌的發生率不斷上升。癌症診斷率的上升推動了對先進免疫療法的需求，其中包括Durvalumab，該藥物以其增強人體對腫瘤免疫反應的能力而聞名。此外，正在進行的旨在拓展度伐Durvalumab適應症和應用的研究和臨床試驗有望進一步提升其市場佔有率。人們對個人化醫療的日益重視也進一步推動了對標靶治療的需求，而Durvalumab正逐漸成為癌症治療方案中不可或缺的一部分。
全球度Durvalumab市場面臨的市場限制
全球度Durvalumab市場的主要限制因素之一是治療費用高昂和醫療資源有限。包括Durvalumab在內的免疫療法價格高昂，會對患者和醫療系統造成沉重的經濟負擔，尤其是在發展中地區，可能會限制其使用。此外，複雜的監管流程和嚴格的新療法核准要求可能會延遲度伐Durvalumab的上市，並限制其供應。這些因素，加上其他替代療法的存在，都為度伐利尤單抗的廣泛應用帶來了挑戰，並阻礙了市場成長潛力。這種經濟負擔會給醫療服務提供者帶來壓力，並導致治療機會不均等。
全球度Durvalumab市場趨勢
全球Durvalumab市場正呈現出一個顯著趨勢，即聯合治療的應用日益普及。腫瘤學家擴大將度Durvalumab與其他查核點抑制劑、標靶治療和化療聯合使用，以增強抗腫瘤效果並改善患者預後。這種由學術界和產業界臨床夥伴關係支持的協作模式，展現出令人矚目的綜效，並鼓勵醫療機構採用多學科綜合治療方案。因此，度Durvalumab的臨床應用範圍正在超越其最初的適應症，加速其在各種癌症治療領域的市場滲透，並與針對不同患者群體的個人化醫療策略的進步保持同步。
目錄
介紹
- 調查目的
- 市場定義和範圍
調查方法
- 研究過程
- 二級資料和一級資料的方法
- 市場規模估算方法
執行摘要
- 全球市場展望
- 市場主要亮點
- 細分市場概覽
- 競爭環境概述
市場動態及展望
- 總體經濟指標
- 促進者和機會
- 抑制因素和挑戰
- 供給面趨勢
- 需求面趨勢
- 波特的分析和影響
關鍵市場分析
- 關鍵成功因素
- 影響市場的因素
- 主要投資機會
- 生態系測繪
- 2025年市場魅力指數
- PESTLE分析
- 監理情勢
Durvalumab全球市場規模：依適應症分類
- 非小細胞肺癌
- 小細胞肺癌
- 膽道癌
- 肝細胞癌
- 其他
度Durvalumab全球市場規模：依治療方法分類
- 單藥治療
- 合併化療
- 聯合免疫療法
- 其他
Durvalumab全球市場規模：按分銷管道分類
- 醫院藥房
- 專科藥房
- 癌症專科藥房
- 其他
度Durvalumab全球市場規模：依最終用戶分類
- 醫院
- 癌症中心
- 專科診所
- 其他
全球度Durvalumab市場規模：依產品類型分類
- 品牌
- 生物相似藥
- 其他
度Durvalumab全球市場規模：依給藥途徑分類
- 靜脈注射
- 醫院管理
- 門診靜脈輸液治療中心
- 其他
全球度Durvalumab市場規模：按地區分類
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
- 拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
- 中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家
競爭資訊
- 前五大公司對比
- 主要公司2025年的市場定位
- 主要市場公司採取的策略
- 近期市場趨勢
- 企業市場占有率分析，2025 年
- 主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）
主要公司簡介
- AstraZeneca plc
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
- Sanofi SA
- Eli Lilly and Company
- BeiGene, Ltd.
- Regeneron Pharmaceuticals, Inc.
- Genmab A/S
- Incyte Corporation
- Exelixis, Inc.
- Arcus Biosciences, Inc.
- Coherus BioSciences, Inc.
- Cullinan Therapeutics, Inc.
- MacroGenics, Inc.
- Immutep Limited
- Compugen Ltd.
結論與建議
Global Durvalumab Market size was valued at USD 1.5 Billion in 2024 and is poised to grow from USD 1.64 Billion in 2025 to USD 3.29 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
Durvalumab, a human IgG1 monoclonal antibody targeting PD-L1, is significantly shaping the immuno-oncology market. Its initial approval for unresectable stage III non-small cell lung cancer (NSCLC), alongside subsequent indications for small-cell lung cancer and urothelial carcinoma, has led to increased physician adoption due to demonstrated superior survival rates compared to standard therapies. AstraZeneca's collaboration with Genentech has enhanced market access across regions, establishing a robust ecosystem involving manufacturers, payers, and oncology centers. Key growth drivers include an expanding indication portfolio that leverages checkpoint blockade mechanisms, alongside ongoing clinical studies in various cancers. Furthermore, AI-driven biomarker discovery is advancing personalized treatment regimens, optimizing patient selection and accelerating clinical uptake, thereby reinforcing Durvalumab's position in the market and encouraging investment.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Durvalumab market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Durvalumab Market Segments Analysis
Global durvalumab market is segmented by indication, therapy type, distribution channel, end user, product type, route of administration and region. Based on indication, the market is segmented into Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma and Others. Based on therapy type, the market is segmented into Monotherapy, Combination with Chemotherapy, Combination with Immunotherapy and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies, Oncology Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Cancer Centers, Specialty Clinics and Others. Based on product type, the market is segmented into Branded, Biosimilar and Others. Based on route of administration, the market is segmented into Intravenous Infusion, Hospital Administration, Ambulatory Infusion Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Durvalumab Market
A key market driver for the global durvalumab market is the increasing prevalence of various cancer types, particularly non-small cell lung cancer (NSCLC) and other solid tumors. This uptick in cancer diagnoses is prompting a growing demand for advanced immunotherapy options, including durvalumab, which is known for its efficacy in enhancing the body's immune response against tumors. Additionally, ongoing research and clinical trials focused on expanding the indications and applications of durvalumab are expected to bolster its market presence. The rising awareness of personalized medicine further fuels the need for targeted therapies, positioning durvalumab as a vital component in oncology treatment protocols.
Restraints in the Global Durvalumab Market
One significant market restraint for the global Durvalumab market is the rising cost of treatment and limited access to healthcare. The high price of immunotherapy drugs, including Durvalumab, can restrict affordability for patients and healthcare systems, particularly in developing regions. Additionally, the complex regulatory processes and stringent approval requirements for new treatments may delay market entry and limit the availability of Durvalumab. These factors, combined with the presence of alternative therapies, create challenges in achieving widespread adoption, thus hindering the market's growth potential. This economic burden places pressure on healthcare providers and can lead to inequities in treatment accessibility.
Market Trends of the Global Durvalumab Market
The Global Durvalumab market is witnessing a significant trend characterized by the expanding adoption of combination therapy. Oncologists are increasingly integrating durvalumab with other checkpoint inhibitors, targeted therapies, and chemotherapy to enhance anti-tumor efficacy and improve patient outcomes. This collaborative approach, bolstered by clinical partnerships across academic and commercial sectors, demonstrates promising synergistic effects that are compelling healthcare providers to adopt multimodal treatment protocols. As a result, durvalumab's clinical applications are expanding beyond initial indications, driving its market penetration across various oncology settings and aligning with the advancing landscape of personalized medicine strategies for patient populations.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Durvalumab Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Biliary Tract Cancer
- Hepatocellular Carcinoma
- Others
Global Durvalumab Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Monotherapy
- Combination with Chemotherapy
- Combination with Immunotherapy
- Others
Global Durvalumab Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
- Oncology Pharmacies
- Others
Global Durvalumab Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Cancer Centers
- Specialty Clinics
- Others
Global Durvalumab Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Branded
- Biosimilar
- Others
Global Durvalumab Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous Infusion
- Hospital Administration
- Ambulatory Infusion Centers
- Others
Global Durvalumab Market Size & CAGR (2026-2033)
- North America (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- US
- Canada
- Europe (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Indication, Therapy Type, Distribution Channel, End User, Product Type, Route of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genmab A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arcus Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coherus BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cullinan Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MacroGenics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Immutep Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Compugen Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
